Oligometastatic Clinical Trials

56 recruitingLast updated: June 18, 2026

There are 56 actively recruiting oligometastatic clinical trials across 33 countries. Studies span Phase 2, Not Applicable, Phase 3, Phase 1, Early Phase 1. Top locations include Toronto, Ontario, Canada, Shanghai, China, Los Angeles, California, United States. Updated daily from ClinicalTrials.gov.


Oligometastatic Trials at a Glance

56 actively recruiting trials for oligometastatic are listed on ClinicalTrialsFinder across 6 cities in 33 countries. The largest study group is Phase 2 with 21 trials, with the heaviest enrollment activity in Toronto, Shanghai, and Los Angeles. Lead sponsors running oligometastatic studies include Mayo Clinic, European Organisation for Research and Treatment of Cancer - EORTC, and British Columbia Cancer Agency.

Browse oligometastatic trials by phase

Treatments under study

About Oligometastatic Clinical Trials

Looking for clinical trials for Oligometastatic? There are currently 2 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Oligometastatic trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Oligometastatic clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 56 trials

Recruiting
Phase 3

An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.

Oligometastatic Prostate Cancer (OMPC)
Novartis Pharmaceuticals450 enrolled147 locationsNCT05939414
Recruiting
Not Applicable

HIghly MetAstatic Life Prolonging Therapy-Resistant Prostate Cancer: Role of Stereotactic Radiotherapy for Bone and Lymph Node Metastases (HIMARS)

Oligometastatic Prostate Cancer (OMPC)Prostate Cancer Metastatic Disease
Institut Cancerologie de l'Ouest18 enrolled1 locationNCT06978296
Recruiting
Phase 2

TERPS Trial for de Novo Oligometastic Prostate Cancer

Prostate CancerOligometastatic Disease
University of Maryland, Baltimore122 enrolled10 locationsNCT05223803
Recruiting
Phase 3

Pembrolizumab and Radiotherapy for Oligometastatic Head and Neck Cancer

Oligometastatic Squamous Cell Carcinoma of the Head and Neck
European Organisation for Research and Treatment of Cancer - EORTC200 enrolled30 locationsNCT05815927
Recruiting
Phase 3

Extending Outcomes for Pancreas Cancer Patients With Nominal Oligometastatic Disease (EXPAND): A Randomized Phase III Trial

Pancreas CancerOligometastatic
M.D. Anderson Cancer Center80 enrolled3 locationsNCT06593431
Recruiting
Phase 1

Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic Cholangiocarcinoma

Stage III Intrahepatic Cholangiocarcinoma AJCC v8Stage IV Intrahepatic Cholangiocarcinoma AJCC v8Unresectable Intrahepatic Cholangiocarcinoma+2 more
Mayo Clinic16 enrolled1 locationNCT06058663
Recruiting
Early Phase 1

Real-Time Atherosclerosis Activity After Thoracic Radiotherapy Using Sodium Fluoride Positron Emission Tomography

Oligometastatic Disease
Katelyn Atkins10 enrolled1 locationNCT06373497
Recruiting
Not Applicable

5500/20 vs. SABR or Brachytherapy for PRimary OligoMetastatic Prostate Cancer Treatment (PROMPT)

Oligometastatic Prostate Cancer
British Columbia Cancer Agency168 enrolled4 locationsNCT04610372
Recruiting
Phase 2

Niraparib Rechallenge After Surgery in Ovarian Cancer Patients With Oligometastatic Progression

Ovarian CancerOligometastatic DiseaseSerous Ovarian Tumor
MedSIR30 enrolled14 locationsNCT06180356
Recruiting
Phase 2

A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer

Breast CancerMetastatic Breast CancerMetastatic Breast Carcinoma+3 more
Memorial Sloan Kettering Cancer Center46 enrolled8 locationsNCT05534438
Recruiting
Not Applicable

Accuracy of 18F-rhPSMA-7.3 PET/ MRI for Prediction of Lymph Node Metastasis in Localized High-Risk Prostate Cancer

Stage III Prostate Cancer AJCC v8Localized Prostate CarcinomaStage I Prostate Cancer AJCC v8+3 more
Mayo Clinic50 enrolled1 locationNCT06389786
Recruiting
Phase 1

Trial of pTVG-HP+Nivo+Targeted Ablation of Resistant Lesions in Non-Castrate RecurrentOMPC

Prostate Cancer PatientsRecurrent Prostate CancerOligometastatic Prostate Cancer (OMPC)+1 more
University of Wisconsin, Madison14 enrolled1 locationNCT07090148
Recruiting
Not Applicable

Single vs. Multiple Fraction Trial of Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastases/Progression

Quality of LifeOligometastatic DiseaseToxicity Due to Radiotherapy+1 more
Robert Olson598 enrolled13 locationsNCT05784428
Recruiting
Phase 1

Trial of Oligometastasis SBRT With Immediate, Simulation-Free Treatment Delivery (OLIGO-SWIFT)

Oligometastatic DiseaseOligometastasis
Case Comprehensive Cancer Center15 enrolled1 locationNCT07079098
Recruiting

Single-Fraction Pulmonary Ablative Radiotherapy Outcomes and Quality-of-life Workup

NSCLC (Non-small Cell Lung Cancer)Oligometastatic Lung TumorSBRT
Institut du Cancer de Montpellier - Val d'Aurelle190 enrolled2 locationsNCT07441941
Recruiting
Phase 3

SBRT Versus Hypofractionated Radiotherapy for Biochemically Recurrent or Oligometastatic Prostate Adenocarcinoma

Stage III Prostate Cancer AJCC v8Stage IV Prostate Cancer AJCC v8Biochemically Recurrent Prostate Carcinoma+4 more
Mayo Clinic118 enrolled6 locationsNCT06205316
Recruiting
Phase 2

A Randomized Trial of Maintenance Systemic Therapy After Radiation for Oligometastatic Renal Cell Carcinoma (ASTROs)

Oligometastatic Renal Cell Carcinoma
M.D. Anderson Cancer Center144 enrolled1 locationNCT06004336
Recruiting
Phase 2

Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study

Stage IVB Prostate Cancer AJCC v8Prostate AdenocarcinomaOligometastatic Prostate Carcinoma+2 more
NRG Oncology194 enrolled239 locationsNCT05053152
Recruiting
Phase 2

Alpha-Emitting Radionuclide or Beta-Emitting Radionuclide With Metastasis-Directed Stereotactic Body Radiotherapy for the Treatment of Recurrent, Oligometastatic Prostate Adenocarcinoma

Recurrent Prostate AdenocarcinomaOligometastatic Prostate Adenocarcinoma
Jonsson Comprehensive Cancer Center107 enrolled1 locationNCT07150715
Recruiting
Not Applicable

Stereotactic Radiotherapy Versus Palliative Conventional Radiotherapy for Oligoprogressive Metastatic Cancers

Oligometastatic DiseaseOligoProgressive Metastatic DiseaseOligoprogression
British Columbia Cancer Agency194 enrolled1 locationNCT06918951